Breast Cancer Diagnostics Industry to Witness 8.2% Growth, Reaching $6.91 Billion by 2029

What are the latest figures on the breast cancer diagnostics market’s size and projected CAGR?

The breast cancer diagnostics market size has grown strongly in recent years. It will grow from $4.68 billion in 2024 to $5.04 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to awareness and screening campaigns, mammography screening, technological advancements, genetic testing, multidisciplinary approach.

The breast cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $6.91 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to personalized medicine, liquid biopsies, 3d mammography (tomosynthesis), ai and machine learning, telemedicine and remote consultations. Major trends in the forecast period include advancements in imaging technologies, personalized medicine, liquid biopsies, ai and machine learning.

Get Your Free Sample of The Global Breast Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3284&type=smp

Which Market drivers have played a significant role in driving the breast cancer diagnostics market?

The increasing incidence of breast cancer will require more equipment to diagnose, which will further increase the demand for the breast cancer diagnostics market. Breast cancer is the most common form of cancer, affecting 2.1 million women every year, and causing the largest number of deaths from cancer in women. The goal of the early diagnosis is to improve the percentage of breast cancers diagnosed at an initial point so that more successful care will be used and the risk of death from breast cancer can be reduced. For instance, in January 2022, according to the American Cancer Society, a US-based health organization that works for cancer elimination, Around 287,850 new instances of invasive breast cancer and 51,400 occurrences of DCIS are estimated to be diagnosed in women in the United States in 2022, with an anticipated 43,250 fatalities due to breast cancer.Therefore, the increasing incidence of breast cancer is expected to drive the growth of the breast cancer diagnostics market.

What are the key segments within the breast cancer diagnostics market?

The breast cancer diagnostics market covered in this report is segmented –

1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types

2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies

3) By Cancer Type: BRCA Breast Cancer, ER And PR Breast Cancer, HER 2 Breast Cancer, EGFR Mutation Test Breast Cancer, Other Cancer Types

4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies

5) By End Users: Hospitals And Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

Subsegments:

1) By Imaging: Mammography, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Tomosynthesis

2) By Biopsy: Needle Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy (FNA), Stereotactic Biopsy

3) By Genomic Tests: Oncotype DX, MammaPrint, PAM50, BRCA1 Or 2 Testing

4) By Blood Tests: Liquid Biopsy, Circulating Tumor DNA (ctDNA) Tests, Circulating Tumor Cells (CTCs) Tests

5) By Other Types: Hormone Receptor Tests, HER2 Tests, Genetic Mutation Testing

Order your report now for swift delivery

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Which key players are shaping the breast cancer diagnostics market?

Major companies operating in the breast cancer diagnostics market include Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Epigenomics AG, AstraZeneca plc, Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

Which transformative trends will shape the breast cancer diagnostics market landscape?

Technological advancement is a key trend in the breast cancer diagnostics market. Several new techniques have been developed which could be used in the diagnosis and treatment of breast cancer. The 3D mammography, also known as breast tomosynthesis, takes photographs around the breast from various angles and translates them into a 3-D model. In September 2022, Niramai, an Indian Health-Tech company, launched an innovative solution called Thermalytix. It is an automated breast cancer screening and diagnostic tool which combines thermal imaging and AI.

How do regional factors impact the breast cancer diagnostics market, and which region is the largest contributor?

North America was the largest region in the breast cancer diagnostics market in 2023. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Does The Breast Cancer Diagnostics Market Report 2025 Offer?

The breast cancer diagnostics market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.

Breast cancer diagnostics refer to the various methods, tests, and procedures used to detect and diagnose breast cancer in individuals. These diagnostics help identify the presence of cancer cells in breast tissue, determine the stage of cancer, and guide treatment decisions.

Purchase the exclusive report now to unlock valuable market insights:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3284

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Leave a Reply

Your email address will not be published. Required fields are marked *